Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3532-3539

  Madeleine, Margaret M ^a,b   Johnson, Lisa G ^a   Smith, Anajane G ^a   Hansen, John A ^a   Nisperos, Brenda B ^a   Li, Sue ^a   Zhao, Lue Ping ^a   Daling, Janet R ^a   Schwartz, Stephen M ^a   Galloway, Denise A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DQ ANTIGEN; HLA DQB1 PROTEIN, HUMAN; HLA-DQB1 PROTEIN, HUMAN; HLA-DRB1 ANTIGEN; MEMBRANE PROTEIN;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE LOCUS; GENOTYPE; HELPER CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VULVA CANCER; ADOLESCENT; AGE DISTRIBUTION; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PREVALENCE; RISK FACTOR; SEXUALITY; SMOKING; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEXUAL PARTNERS; SMOKING; UTERINE CERVICAL NEOPLASMS;

EID: 44849109005     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6471     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995;64:277-82.
3. Mota F, Rayment N, Chong S, Singer A, Chain B. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999;116:33-40.
4. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-9.
5. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61:1934-40.
6. Daling JR, Madeleine MM, McKnight B, et al. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev 1996;5:541-8.
7. 72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 2000;9:225-7.
8. Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007;120:650-5.
9. Madeleine MM, Brumback B, Cushing-Haugen KL, et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002;186:1565-74.
10. Olson SH, Voigt LF, Begg CB, Weiss NS. Reporting participation in case-control studies. Epidemiology 2002;13:123-6.
11. Hall MA, Lanchbury JS, Lee JS, Welsh KI, Ciclitira PJ. HLA-DQ2 second-domain polymorphisms may explain increased trans-associated risk in celiac disease and dermatitis herpetiformis. Hum Immunol 1993;38:284-92.
12. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
13. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996;86:726-8.
14. Madeleine MM, Daling JR, Schwartz SM, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001;10:171-7.
15. Madeleine MM, Daling JR, Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997;89:1516-23.
16. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 1999;80:399-408.
17. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002;89:229-40.
18. de Araujo Souza PS, Villa LL. Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat Res 2003;544:375-83.
19. Zoodsma M, Nolte IM, Schipper M, et al. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet 2005;42:e49.
20. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet 2004;13:1951-8.
21. Hildesheim A, Schiffman M, Scott DR, et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:1035-41.
22. Wang SS, Wheeler CM, Hildesheim A, et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001;184:1310-4.
23. Carreon JD, Martin MP, Hildesheim A, et al. Human leukocyte antigen class I and II haplotypes and risk of cervical cancer. Tissue Antigens 2005;66:321-4.
24. Duggan-Keen MF, Keating PJ, Stevens FR, et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet 1996;23:275-84.
25. Ellis JR, Keating PJ, Baird J, et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1995;1:464-70.
26. Malhotra U, Holte S, Dutta S, et al. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001;107:505-17.
27. Davenport MP, Quinn CL, Chicz RM, et al. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR β chain. Proc Natl Acad Sci U S A 1995;92:6567-71.
28. Marsh SGE, Parham P, Barber LD. The HLA Facts-Book. San Diego: Academic Press; 2000.